JP2021501766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501766A5 JP2021501766A5 JP2020524501A JP2020524501A JP2021501766A5 JP 2021501766 A5 JP2021501766 A5 JP 2021501766A5 JP 2020524501 A JP2020524501 A JP 2020524501A JP 2020524501 A JP2020524501 A JP 2020524501A JP 2021501766 A5 JP2021501766 A5 JP 2021501766A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- crystal
- composition according
- composition
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023070786A JP7499377B2 (ja) | 2017-11-02 | 2023-04-24 | 共結晶、その医薬組成物、およびそれを伴う治療方法 |
| JP2024090124A JP7780576B2 (ja) | 2017-11-02 | 2024-06-03 | 共結晶、その医薬組成物、およびそれを伴う治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580501P | 2017-11-02 | 2017-11-02 | |
| US62/580,501 | 2017-11-02 | ||
| PCT/US2018/058930 WO2019090059A1 (en) | 2017-11-02 | 2018-11-02 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023070786A Division JP7499377B2 (ja) | 2017-11-02 | 2023-04-24 | 共結晶、その医薬組成物、およびそれを伴う治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501766A JP2021501766A (ja) | 2021-01-21 |
| JP2021501766A5 true JP2021501766A5 (enExample) | 2021-12-16 |
| JP7335877B2 JP7335877B2 (ja) | 2023-08-30 |
Family
ID=64572453
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524501A Active JP7335877B2 (ja) | 2017-11-02 | 2018-11-02 | 共結晶、その医薬組成物、およびそれを伴う治療方法 |
| JP2023070786A Active JP7499377B2 (ja) | 2017-11-02 | 2023-04-24 | 共結晶、その医薬組成物、およびそれを伴う治療方法 |
| JP2024090124A Active JP7780576B2 (ja) | 2017-11-02 | 2024-06-03 | 共結晶、その医薬組成物、およびそれを伴う治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023070786A Active JP7499377B2 (ja) | 2017-11-02 | 2023-04-24 | 共結晶、その医薬組成物、およびそれを伴う治療方法 |
| JP2024090124A Active JP7780576B2 (ja) | 2017-11-02 | 2024-06-03 | 共結晶、その医薬組成物、およびそれを伴う治療方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11345677B2 (enExample) |
| EP (1) | EP3704101A1 (enExample) |
| JP (3) | JP7335877B2 (enExample) |
| KR (2) | KR102731624B1 (enExample) |
| CN (2) | CN118359585A (enExample) |
| AU (2) | AU2018360827B2 (enExample) |
| BR (1) | BR112020008598A2 (enExample) |
| CA (1) | CA3081535A1 (enExample) |
| EA (1) | EA202091112A1 (enExample) |
| IL (2) | IL305426B2 (enExample) |
| MA (1) | MA50526A (enExample) |
| MX (2) | MX2020004513A (enExample) |
| PH (1) | PH12020550462A1 (enExample) |
| SG (1) | SG11202003612VA (enExample) |
| TW (2) | TWI839131B (enExample) |
| UA (1) | UA127380C2 (enExample) |
| WO (1) | WO2019090059A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085832A1 (en) * | 2019-11-22 | 2020-03-19 | Agios Pharmaceuticals, Inc. | Deuterated analogs of an organic compound |
| TW202227446A (zh) | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | 有機化合物之固態形式 |
| US20230346789A1 (en) | 2022-03-31 | 2023-11-02 | Msd International Gmbh | Methods of treating enhancing brain tumors using combination therapy |
| AR133332A1 (es) | 2023-07-25 | 2025-09-17 | Servier Lab | Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos |
| WO2025060940A1 (zh) * | 2023-09-18 | 2025-03-27 | 贝达药业股份有限公司 | 突变型idh抑制剂化合物及其盐的固体形式 |
| EP4538262A1 (en) | 2023-10-12 | 2025-04-16 | Sandoz Ag | Cocrystals of vorasidenib |
| US20250257050A1 (en) | 2024-02-09 | 2025-08-14 | Les Laboratoires Servier | Process for the preparation of vorasidenib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ710636A (en) * | 2010-11-01 | 2017-02-24 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
| WO2015003360A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) * | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
-
2018
- 2018-11-02 TW TW112106677A patent/TWI839131B/zh active
- 2018-11-02 AU AU2018360827A patent/AU2018360827B2/en active Active
- 2018-11-02 CN CN202410230044.7A patent/CN118359585A/zh active Pending
- 2018-11-02 IL IL305426A patent/IL305426B2/en unknown
- 2018-11-02 MA MA050526A patent/MA50526A/fr unknown
- 2018-11-02 CN CN201880079771.0A patent/CN111527076B/zh active Active
- 2018-11-02 KR KR1020207015661A patent/KR102731624B1/ko active Active
- 2018-11-02 JP JP2020524501A patent/JP7335877B2/ja active Active
- 2018-11-02 KR KR1020247037879A patent/KR20240166601A/ko active Pending
- 2018-11-02 EA EA202091112A patent/EA202091112A1/ru unknown
- 2018-11-02 BR BR112020008598-7A patent/BR112020008598A2/pt active IP Right Grant
- 2018-11-02 US US16/760,520 patent/US11345677B2/en active Active
- 2018-11-02 TW TW107139079A patent/TWI796377B/zh active
- 2018-11-02 CA CA3081535A patent/CA3081535A1/en active Pending
- 2018-11-02 WO PCT/US2018/058930 patent/WO2019090059A1/en not_active Ceased
- 2018-11-02 SG SG11202003612VA patent/SG11202003612VA/en unknown
- 2018-11-02 UA UAA202003279A patent/UA127380C2/uk unknown
- 2018-11-02 IL IL274123A patent/IL274123B2/en unknown
- 2018-11-02 MX MX2020004513A patent/MX2020004513A/es unknown
- 2018-11-02 EP EP18812419.2A patent/EP3704101A1/en active Pending
-
2020
- 2020-04-22 PH PH12020550462A patent/PH12020550462A1/en unknown
- 2020-07-13 MX MX2022014792A patent/MX2022014792A/es unknown
-
2022
- 2022-04-19 US US17/723,666 patent/US11851417B2/en active Active
-
2023
- 2023-04-24 JP JP2023070786A patent/JP7499377B2/ja active Active
- 2023-11-08 US US18/504,859 patent/US20240343705A1/en active Pending
-
2024
- 2024-05-14 AU AU2024203186A patent/AU2024203186A1/en active Pending
- 2024-06-03 JP JP2024090124A patent/JP7780576B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501766A5 (enExample) | ||
| CN112912077B (zh) | 用于治疗三阴性乳腺癌的组合疗法 | |
| JP7668777B2 (ja) | 癌治療 | |
| TWI798199B (zh) | 癌症治療 | |
| JP2019517487A5 (enExample) | ||
| TWI594986B (zh) | Antineoplastic agent effect enhancer | |
| CN109937041B (zh) | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2015512942A5 (enExample) | ||
| EA031116B1 (ru) | КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ | |
| JP2018531280A5 (enExample) | ||
| IL274123B2 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| JP6855488B2 (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| CN116323590A (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| US20220213014A1 (en) | Crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol | |
| CN102812010A (zh) | 喹唑啉衍生物及其制备方法和应用 | |
| JP7441214B2 (ja) | 前立腺がんの治療のための併用療法 | |
| TW202027750A (zh) | 治療癌症之套組及其方法 | |
| JPWO2022132652A5 (enExample) | ||
| JPWO2019195753A5 (enExample) | ||
| TWI848990B (zh) | 治療化療難治性癌症的新聯合用藥方案 | |
| JP2024505252A (ja) | Ｐｔｅｎ不活性化突然変異を有する患者における癌の治療 | |
| CN119569705B (zh) | Ptk抑制剂a的磷酸盐及应用 | |
| US11390601B2 (en) | Conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for cancer treatment | |
| WO2024068467A1 (en) | Tetrahydroquinoline compounds as antitumor agents | |
| TW202241846A (zh) | 具有ｅｐ拮抗活性之化合物的鹽、溶劑合物及結晶 |